Tipifarnib aids in downregulating CXCL12 secretion; when trialed in a cohort of CXCL12-overexpressed AITL patients, a 43% ORR and 73% CBR was observedPresence of the KIR3DL2 gene variants additionally predicted complete response to tipifarnib therapy and improved outcomes. The gene discussed is KIR3DL2; the disease is angioimmunoblastic T-cell lymphoma.